Polymyxin B for endotoxin removal in sepsis

The Lancet Infectious Diseases

Volumn 11, Issue 6, 2011, Pages 426-427

  Cavaillon, Jean Marc ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; INTERLEUKIN 1; POLYMYXIN B;

ACINETOBACTER CALCOACETICUS; BORDETELLA PERTUSSIS; ESCHERICHIA COLI; HUMAN; LETTER; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERITIDIS; SEPSIS;

BACTERIAL INFECTIONS; ENDOTOXINS; HEMOPERFUSION; HUMANS; POLYMYXIN B; SHOCK, SEPTIC;

EID: 79956268635     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70131-1     Document Type: Letter

References (5)

1. Davies B, Cohen J Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 2011, 11:65-71.
2. Laude-Sharp M, Haeffner-Cavaillon N, Caroff M, Lantreibecq F, Pusineri C, Kazatchkine MD Dissociation between the interleukin-1-inducing capacity and Limulus reactivity of lipopolysaccharides from Gram-negative bacteria. Cytokine 1990, 2:253-258.
3. Cavaillon JM, Haeffner-Cavaillon N Polymyxin-B inhibition of LPS-induced interleukin-1 secretion by human monocytes is dependent upon the LPS origin. Mol Immunol 1986, 23:965-969.
4. Baldwin G, Alpert G, Caputo GL, et al. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins. J Infect Dis 1991, 164:542-549.
5. Evans TJ, Carpenter A, Moyes D, Martin R, Cohen J Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of gram-negative sepsis. J Infect Dis 1995, 171:153-160.